The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a randomized, double-blind, placebo-controlled study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ghamra Military Hospital
• Collaborator: Ain Shams Maternity Hospital
• Treatments: Progesterone

Criteria

Inclusion Criteria:

1. Singleton pregnancies.

2. Gestational age, on admission, is between 14 and 18 weeks.

3. Past history of at least one idiopathic preterm birth.

Exclusion Criteria:

1. Established preterm labor (cervical dilatation ≥ 4 cm).

2. Persistent uterine contractions.

3. Women with medical or surgical complications indicating delivery or termination of pregnancy.

4. Presence of fetal anomalies incompatible with life.

5. Premature rupture of membranes.